Acotiamide
Small moleculeexperimental
Clinical trial activity
14 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
10
Phase 3
5
Phase 4
0
Earliest trial started Mar 1, 2004 (NCT00102310)
Timeline
Indications
Mechanism of action
- Muscarinic acetylcholine receptor M2INHIBITOR
CHRM2 inhibitor
- Muscarinic acetylcholine receptor M1INHIBITOR
CHRM1 inhibitor
- AcetylcholinesteraseINHIBITOR
Acetylcholinesterase inhibitor
Reversible inhibitor.
Selective for AChE over BuChE.
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(O)c(C(=O)Nc2nc(C(=O)NCCN(C(C)C)C(C)C)cs2)cc1OC- Mol. weight
- 450.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107723 ↗
- ChEMBLCHEMBL2107308 ↗
Also known as
- acofide
- acotiamide
- acotiamide
- acotiamide
- acotiamide
- acotiamide
- acotiamide
- acotiamide hcl
- acotiamide hcl
- acotiamide hcl
- acotiamide hydrochloride
- acotiamide hydrochloride
- acotiamide hydrochloride
- acotiamide hydrochloride hydrate
- n-(n',n'-diisopropylaminoethyl)-(2-(2-hydroxy-4,5-dimethoxybenzoylamino)-1,3-thiazole-4-yl)carboxyamide
- ym443
- ym443
- ym 443
- ym-443
- ym-443
- ym-443
- ym443 cpd
- z 338
- z-338
- z-338
- z-338
- z-338
- z-338
- z-338
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07174297 | Phase 3 | Oct 30, 2025 | Getz Pharma, Rawalpindi Medical College, Pakistan |
| NCT04526119 | Phase 3 | Feb 22, 2021 | Zeria Pharmaceutical |
| NCT04697641 | N/A | Sep 1, 2017 | Sir Ganga Ram Hospital |
| NCT03402984 | N/A | Apr 1, 2017 | Katholieke Universiteit Leuven |
| NCT01973790 | Phase 3 | Mar 1, 2014 | Katholieke Universiteit Leuven, Zeria Pharmaceutical |
| NCT00920998 | Phase 1 | Mar 1, 2009 | Astellas |
| NCT00850746 | Phase 1 | Feb 1, 2009 | Astellas |
| NCT00761358 | Phase 3 | Sep 1, 2008 | Tohoku University, Zeria Pharmaceutical |
| NCT00764374 | Phase 3 | Aug 1, 2008 | Astellas |
| NCT00458328 | Phase 2 | Apr 1, 2007 | Kawasaki Medical University, Zeria Pharmaceutical |
| NCT00333372 | Phase 2 | Apr 1, 2006 | Tohoku University, Zeria Pharmaceutical |
| NCT00323817 | Phase 2 | Apr 1, 2006 | Katholieke Universiteit Leuven, Zeria Pharmaceutical |
| NCT00298194 | Phase 2 | Feb 1, 2006 | University of Adelaide, Zeria Pharmaceutical |
| NCT00102310 | Phase 2 | Mar 1, 2004 | Astellas |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zeria Pharmaceutical | For profit | 7 | 7 | 2 | 2006 |
| Astellas | For profit | 4 | 4 | 3 | 2004 |
| Katholieke Universiteit Leuven | Academic/Hospital | 3 | 1 | 3 | 2006 |
| Tohoku University | Academic/Hospital | 2 | 0 | 2 | 2006 |
| Getz Pharma | For profit | 1 | 1 | 1 | 2025 |
| Kawasaki Medical University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Rawalpindi Medical College, Pakistan | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Sir Ganga Ram Hospital | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Adelaide | Academic/Hospital | 1 | 0 | 1 | 2006 |
9 organizations
Page 1 / 1